Akcea Therapeutics (NASDAQ: AKCA) is one of 100 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Akcea Therapeutics to related companies based on the strength of its analyst recommendations, institutional ownership, dividends, valuation, earnings, profitability and risk.
This table compares Akcea Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Akcea Therapeutics Competitors||-2,467.64%||-66.41%||-8.36%|
Valuation and Earnings
This table compares Akcea Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Akcea Therapeutics||N/A||-$83.21 million||-4.54|
|Akcea Therapeutics Competitors||$8.46 billion||$1.13 billion||126.81|
Akcea Therapeutics’ peers have higher revenue and earnings than Akcea Therapeutics. Akcea Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and recommmendations for Akcea Therapeutics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Akcea Therapeutics Competitors||861||3762||6730||177||2.54|
Akcea Therapeutics currently has a consensus target price of $24.00, indicating a potential upside of 34.23%. As a group, “Pharmaceuticals” companies have a potential upside of 23.95%. Given Akcea Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Akcea Therapeutics is more favorable than its peers.
Insider and Institutional Ownership
0.5% of Akcea Therapeutics shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.0% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Akcea Therapeutics beats its peers on 6 of the 11 factors compared.
About Akcea Therapeutics
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company’s volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company’s clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.